Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

Vertex Pharmaceuticals (VRTX) closed at $435.76 in the latest trading session, marking a -2.25% move from the prior day. The stock's change was less than the S&P 500's daily loss of 1.62%. Elsewhere, the Dow saw a downswing of 1.87%, while the tech-heavy Nasdaq depreciated by 1.98%. Coming into today, shares of the drugmaker had lost 0.56% in the past month. In that same time, the Medical sector gained 5.04%, while the S&P 500 lost 0.03%. Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company is expected to report EPS of $4.79, up 5.97% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.22 billion, up 8.46% from the year-ago period. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $19.15 per share and a revenue of $13.03 billion, representing changes of +4.08% and +8.57%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.16% higher. Vertex Pharmaceuticals is currently a Zacks Rank #3 (Hold). In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 23.28. This denotes a premium relative to the industry average Forward P/E of 21.35. Investors should also note that VRTX has a PEG ratio of 1.69 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.51 as trading concluded yesterday. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 37% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks